CollabRx, Sengenics Partner on Cancer Diagnostics | GenomeWeb

NEW YORK (GenomeWeb News) – CollabRx today announced a deal with Sengenics to incorporate each other's products into molecular diagnostics tests and reports aimed at cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.